Explore the efficacy and mechanism of cabozantinib

Cabozantinib is a powerful targeted therapy drug. As a tyrosine kinase inhibitor, it has demonstrated significant efficacy in the treatment of a variety of malignant tumors. Its main mechanism of action is to prevent tumor cell metastasis, angiogenesis and tumor occurrence by inhibiting specific receptor tyrosine kinases. The targets of cabozantinib include VEGFR (vascular endothelial growth factor receptor), MET, AXL, etc. These receptors play an important role in the growth and spread of tumor cells.

In clinical studies, cabozantinib showed significant improvement in patients with progressive metastatic medullary thyroid carcinoma (MTC). The study results showed that compared with the placebo group, the progression-free survival (PFS) of the cabozantinib group was significantly prolonged from 4 months to 11.2 months (P<.001), which provides new hope for patients. In addition, in patients with advanced renal cell carcinoma whose disease progressed after previous treatment with VEGFR tyrosine kinase inhibitors (ITK), cabozantinib also showed longer overall survival (OS) than everolimus, 21.4 months versus 16.5 months (P<.0003), further proving its potential in the treatment of advanced renal cell carcinoma.

Cabozantinib is approved for the treatment of progressive metastatic MTC and advanced renal cell carcinoma, providing an effective treatment option for these patients. The drug was tolerated similarly to traditional anti-angiogenic therapies and showed good results in managing side effects. When patients use cabozantinib, they need to do so under the guidance of a doctor to ensure the safety and effectiveness of the treatment.

All in all, cabozantinib, with its unique targeting effect, brings new hope to patients with various types of malignant tumors. With in-depth research on this drug, it is expected that more indications will be discovered in the future and effective treatment options will be provided for more patients.

Reference:https://en.wikipedia.org/wiki/Cabozantinib